Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.39 |
| ▸ | HPGD | P15428 | 8/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767417 | 0.94 | TDP1 (0.44) | TDP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5675554 | 0.87 | TDP1 (0.42) | TDP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29419658 | 0.87 | TDP1 (0.42) | TDP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29364275 | 0.86 | KDM4E (0.53) | TDP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL4755762 | 0.86 | KDM4E (0.53) | TDP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL15571611 | 0.85 | TDP1 (0.44) | TDP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29543547 | 0.85 | TDP1 (0.44) | TDP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30887566 | 0.82 | CA12 (0.48) | TDP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL614030 | 0.82 | TDP1 (0.36) | TDP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30205792 | 0.81 | KDM4E (0.58) | TDP1KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179031-A1 | PROTEASOME ENHANCERS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2025-06-05 | — | — | US | disclosed |
| US-20240043394-A1 | PROTEASOME ENHANCERS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2024-02-08 | — | — | US | disclosed |
| US-20230295116-A1 | PROTEASOME ENHANCERS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2023-09-21 | — | — | US | disclosed |
| US-20230286982-A1 | PROTEASOME ENHANCERS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| WO-2023147485-A2 | PROTEASOME ENHANCERS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-4196121-A1 | PROTEASOME ENHANCERS AND USES THEREOF | Board Of Trustees Of Michigan State University (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-4196464-A1 | PROTEASOME ENHANCERS AND USES THEREOF | Board Of Trustees Of Michigan State University (US) | 2023-06-21 | — | — | EP | disclosed |
| CN-116194158-A | Biological indicator comprising genetically modified test microorganism | 3M创新有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-114981399-A | Self-contained biological indicator with salt compound | 3M创新有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2022035902-A1 | PROTEASOME ENHANCERS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20050158302-A1 | Methods for diagnosing and treating autoimmune disease | GENERAL HOSPITAL CORPORATION | 2005-07-21 | — | — | US | disclosed |
| US-6773705-B1 | RESTORING NF KAPPA B ACTIVITY | GENERAL HOSPITAL CORPORATION | 2004-08-10 | — | — | US | disclosed |
| US-20040136945-A1 | Use of phaeodactylum algae extract as cosmetic agent promoting the proteasome activity of skin cells and cosmetic composition comprising same | LYMH RECHERCHE (FR) | 2004-07-15 | — | — | US | disclosed |
| US-20030186948-A1 | O-linked N-acetylglucosamine pathway in the pathogenesis of neurodegeneration and diabetes | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-10-02 | — | — | US | disclosed |
| US-6617171-B2 | Detecting immunological defects in mammal; obtain sample tissue from mammal, detect proteasome activity, reduction in proteasome activty indicates immunological defect | THE GENERAL HOSPITAL CORPORATION | 2003-09-09 | — | — | US | disclosed |
| US-20020106689-A1 | METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-08-08 | — | — | US | disclosed |
| US-5972636-A | SCREENING FOR MULTIPAIN ENZYME INHIBITORS BY CONTACTING CULTURED CELLS WITH TEST SUBSTANCE, AND MEASURING PROTEIN IN CYTOSOL WHOSE DEGRADATION IS UBIQUITIN DEPENDENT; ACCUMULATION INDICATES PRESENCE OF ENZYME INHIBITOR | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-10-26 | — | — | US | disclosed |
| US-5565351-A | REDUCING THE MUSCLE PROTEIN LOSS BY REDUCING PROTEOLYSIS | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1996-10-15 | — | — | US | disclosed |
| US-5340736-A | Multipain and multipain-proteasome complex which cleave ubiquinated and non-ubiquinated proteins | THE PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 1994-08-23 | — | — | US | disclosed |
| WO-1992020804-A1 | ATP-DEPENDENT PROTEASE AND USE OF INHIBITORS FOR SAME IN THE TREATMENT OF CACHEXIA AND MUSCLE WASTING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286982-A1 | PROTEASOME ENHANCERS AND USES THEREOF | PSME3, PSME1, PSME4 | TDP1 466/4885KDM4E 823/4885ALDH1A1 3557/4885 |
| US-20250179031-A1 | PROTEASOME ENHANCERS AND USES THEREOF | PSME3, PSMG3, PSME1 | TDP1 415/4885KDM4E 1302/4885ALDH1A1 2894/4885 |
| US-20230295116-A1 | PROTEASOME ENHANCERS AND USES THEREOF | PSME3, PSME4, ADRM1 | TDP1 1028/4885KDM4E 839/4885ALDH1A1 2806/4885 |
| US-20240043394-A1 | PROTEASOME ENHANCERS AND USES THEREOF | PSME3, PSME1, PSMB5 | TDP1 479/4885KDM4E 853/4885ALDH1A1 2708/4885 |
| US-20040136945-A1 | Use of phaeodactylum algae extract as cosmetic agent promoting the proteasome activity of skin cells and cosmetic composition comprising same | PSMG3, PSME1, PSMB5 | TDP1 1252/4885KDM4E 1050/4885ALDH1A1 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.